Submitted by Anjali Fortna on Tue, 05/26/2015 - 2:43pm Currently, how confident are you in your ability to * Please use the scale: 1=NOT at all confident, 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=EXTREMELY confident 12345 Develop personalized treatment plans for patients with metastatic melanoma? Develop personalized treatment plans for patients with metastatic melanoma? - 1 Develop personalized treatment plans for patients with metastatic melanoma? - 2 Develop personalized treatment plans for patients with metastatic melanoma? - 3 Develop personalized treatment plans for patients with metastatic melanoma? - 4 Develop personalized treatment plans for patients with metastatic melanoma? - 5 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 1 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 2 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 3 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 4 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 5 The coBRIM study was a large, phase III randomized trial of vemurafenib (VEM) plus cobimetinib (COBI) vs. vemurafenib alone. The results of the study showed that VEM plus COBI had a significantly greater median progression free survival than vemurafenib alone. What was the progression free survival of VEM & COBI and what was that of VEM alone? * VEM + COBI = 10 months; VEM alone = 5 months VEM + COBI= 12 months; VEM alone= 7 months VEM + COBI = 12 months; VEM alone = 4 months VEM + COBI = 2 years; VEM alone = 1 year Combi-V was a randomized, open-label Phase III study of dabrafenib (D) and trametinib (T) vs. vemurafenib (VEM) for first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Which of the following was NOT a conclusion drawn from this study? * Dabrafenib and trametinib resulted in improved overall survival compared to vemurafenib monotherapy The median survival rate was greater than 24 months Patients with low LDH did not do very well with the combination therapy All of these conclusions are correct NRAS –mutant melanoma is a prevalent form of melanoma, second only to BRAF mutations. Approximately what percentage of melanoma patients will have NRAS mutation? * 10% 20% 30% 40% True or False. The CheckMate 064 study is an open-label, randomized, phase II study of patients given either nivolumab first followed by ipilimumab or ipilimumab as monotherapy followed by nivolumab. Patients treated with ipilimumab as monotherapy followed by nivolumab had higher response rates at both week 13 and week 25 of this study. * True False There has recently been some promising ipilimumab, phase II data that could alter the way the metastatic melanoma patient is treated in the coming years. Which of the following was not a promising future agent mentioned? * Idoleamine 2,3 dioxygenase (IDO) Granulocyte-macrophage colony-stimulating factor (GM-CSF) Interlukin-2 All of the above are promising future agents In the updated results of a phase 1/2 study presented at ECC 2015 of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma, what was the overall response rate for previously untreated patients? * 10% 20% 30% 50% True of False. The abscopal effect occurs when a tumor is eradiated and then the patient experiences regression outside of that eradiated area. * True False Please take a moment to reflect on your current use of the practice strategies discussed in this activity. You will not be graded on your responses. Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with metastatic melanoma. * 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable for me 12345N/A Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 1 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 2 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 3 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 4 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 5 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - N/A Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 1 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 2 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 3 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 4 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 5 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - N/A Leave this field blank
